Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment.
Hoek
K G P
KG
DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University. kimd@sun.ac.za
Schaaf
H S
HS
Gey van Pittius
N C
NC
van Helden
P D
PD
Warren
R M
RM
D000995:Antitubercular Agents / Q000008:administration & dosage*; D023801:Directly Observed Therapy / Q000592:standards; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage*; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008826:Microbial Sensitivity Tests; D011718:Pyrazinamide / Q000008:administration & dosage*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol